High-Dose Flu Vaccine Reduces Hospitalization Risk in LTC Residents

November 4, 2016

In a presentation given at IDWeek 2016, Fluzone High-Dose vaccine reduced the risk of all-cause hospitalization as well as hospitalization for respiratory conditions among long-term care residents, compared with the standard-dose Fluzone vaccine.

For their study, lead author Stefan Gravenstein, MD, MPH, of Warren Alpert Medical School, Brown University (Providence, RI) and colleagues sought to determine whether or not a more immunogenic vaccine would reduce hospitalizations among nursing home residents.

Using data from the Center for Medicare & Medicaid Services and from enrolled facilities, they analyzed intent-to-treat hospitalization incidence using marginal Poisson regression, accounting for clustering of residents within facilities, and adjusting for a priori facility and resident covariates. Secondary outcomes included mortality and activities of daily living.

The study randomly assigned 823 facilities in 38 states with 53,008 long-stay residents to administer either high-dose or standard-dose vaccines for the 2013–2014 season. Analyses included residents age 65 years or older who had lived in the facilities for more than 90 days. During the study period, flu A/H1N1 was the dominant strain.

The research team found fewer all-cause hospitalizations in high-dose group patients compared with standard-dose facilities for all-causes. And all-causes mortality was similar between the two groups.—Amanda Del Signore